ONCOLYTICS BIOTECH INC | CIK:0001129928 | 3

  • Filed: 3/19/2018
  • Entity registrant name: ONCOLYTICS BIOTECH INC (CIK: 0001129928)
  • Generator: Workiva (WebFilings)
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/0001129928-18-000028-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/oncyf-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001129928
  • Open this page in separate window: Click

    • ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory

    As at December 31, 2017, we have the following non-capital losses for income tax purposes in Canada:
    Expiry
    $
    2026
    9,809,000

    2027
    12,170,000

    2029
    4,009,000

    2030
    4,774,000

    2031
    4,343,000

    2032
    2,873,000

    2033
    2,457,000

    2034
    2,472,000

    2035
    3,125,000

    2036
    6,430,000

    2037
    4,846,000

     
    57,308,000













    As at December 31, 2017, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:

    Expiry
    $
    2020
    189,000

    2021
    471,000

    2022
    465,000

    2023
    361,000

    2024
    228,000

    2025
    271,000

    2026
    520,000

    2027
    596,000

    2028
    622,000

    2029
    173,000

    2030
    91,000

    2031
    114,000

    2032
    381,000

    2033
    487,000

    2034
    270,000

    2035
    183,000

    2036
    41,000

    2037
    600


    5,463,600

    Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:
     
    2017
    $
    2016
    $
    2015
    $
    Net operating losses carried forward
    19,160,218

    17,821,631

    15,950,044

    Scientific research and experimental development
    7,406,099

    7,394,707

    7,278,284

    Investment tax credits
    3,988,325

    3,990,664

    3,987,214

    Undepreciated capital costs in excess of book value of property and equipment and intellectual property
    1,927,640

    1,908,654

    1,839,107

    Share issue costs
    493,343

    432,659

    619,066

    Net capital losses carried forward
    7,598

    7,598

    7,598

    Unrecognized deferred tax asset
    32,983,223

    31,555,913

    29,681,313